Ibrutinib may impair serological responses to influenza vaccination

Douglas, Abby; Trubiano, Jason A; Barr, Ian G.; Leung, Vivian; Slavin, Monica A; Tam, Constantine S.

doi:10.3324/haematol.2017.164285

Cited by 81 publications

(80 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sorafenib (Multikinase-Inhibitor (RAF-Kinase-und VEGFR-Inhibitor)) behandelt wurden, war die Immunantwort ähnlich der gesunder Erwachsener [242]. Douglas et al konnte in ihrer Studie hingegen keine Immunantwort auf die Impfung unter der Gabe von Ibrutinib feststellen [88]. Aufgrund dieser Beobachtungen wird empfohlen, bei einer Impfung mit einem Influenzatotimpfstoff unter TKI-Gabe eine 2.…”

Section: Impfen Bei Therapie Mit Tyrosinkinaseinhibitorenunclassified

Impfen bei Immundefizienz

Laws

Baumann

Bogdan

et al. 2020

Bundesgesundheitsbl

View full text Add to dashboard Cite

Section: Impfen Bei Therapie Mit Tyrosinkinaseinhibitorenunclassified

Impfen bei Immundefizienz

Laws

Baumann

Bogdan

et al. 2020

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…One study of influenza vaccination in 19 patients on single agent ibrutinib found that 26% had seroconversion to at least one vaccine strain 51 . A subsequent study looking at 13 relapsed CLL patients on ibrutinib for median 7.5 months found no responders to influenza vaccine 52 . A similar study of 13-valent pneumococcal conjugate vaccination (PCV-13) found that all four untreated patients responded, while none of the four ibrutinib patients did, suggesting that if possible to vaccinate prior to starting ibrutinib, this is preferred 53 .…”

Section: Infections and Prophylaxis (Including Vaccines)mentioning

confidence: 98%

How I treat CLL patients with ibrutinib

Brown

2018

Blood

View full text Add to dashboard Cite

Ibrutinib is a transformative therapy for high-risk and relapsed refractory chronic lymphocytic leukemia (CLL) patients. In clinical trials in relatively healthy younger patients, ibrutinib has been well tolerated. As its use has become more widespread in the community, however, its full adverse event profile has emerged and proven more challenging than was initially anticipated. Reports of community-based use have estimated discontinuation rates as high as 40% in the first year of therapy. This article therefore reviews my approach to the evaluation and management of a CLL patient starting on ibrutinib, with the goal of minimizing and managing toxicity to maintain patients on ibrutinib. Key topics discussed include bleeding risk; cardiac complications, particularly atrial fibrillation; drug interactions; and infections.

show abstract

“…Immune response to vaccine may be attenuated in patients on efalizumab, 78 BCR-ABL tyrosine kinase inhibitors, 79 tofacitinib 80 and ibrutinib. 81 Patients treated with vedolizumab have shown reduced response to oral vaccines but not injectable ones. 42 Interestingly, mTOR inhibitors have been shown to enhance immune response to certain vaccines.…”

Section: Immunization In Patients On Biologic and Targeted Immunomodumentioning

confidence: 99%

<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>

Kordzadeh-Kermani

Khalili

Karimzadeh

et al. 2020

IDR

View full text Add to dashboard Cite

The introduction of biologic and targeted immunomodulators is a significant breakthrough in the therapeutic area of various fields of medicine. The occurrence of serious infections, a complication of secondary immunosuppression associated with these agents, leads to increased morbidity and mortality. Implementing preventive strategies could minimize infection-related complications and improve therapeutic outcomes. The purpose of this review is to focus on current evident approaches regarding screening, monitoring, preventing (immunization and chemoprophylaxis), and management of infections in patients who are candidates for about 70 biologic and targeted immunomodulators. Recommendations are based on relevant guidelines, especially the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document series published in 2018.

show abstract

Ibrutinib may impair serological responses to influenza vaccination

Cited by 81 publications

References 14 publications

Impfen bei Immundefizienz

Impfen bei Immundefizienz

How I treat CLL patients with ibrutinib

<p>Prevention Strategies to Minimize the Infection Risk Associated with Biologic and Targeted Immunomodulators</p>

Contact Info

Product

Resources

About